Evidence map›Paper›PMID 42487068›Full record

ArticleClinical pharmacokinetics2026

Low Tacrolimus C

Amar D Levens, Teun van Gelder, Armin Gelinck, Soufian Meziyerh, Aiko P J de Vries, Danny van der Helm, Jesse J Swen, Dirk Jan A R Moes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amar D LevensDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands.
Teun van GelderDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands.
Armin GelinckDivision of Nephrology, Department of Internal Medicine, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands.
Soufian MeziyerhDivision of Nephrology, Department of Internal Medicine, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands.
Aiko P J de VriesDivision of Nephrology, Department of Internal Medicine, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands.
Danny van der HelmLeiden Transplant Center, Leiden University Medical Center and Leiden University, 2333 ZA, Leiden, The Netherlands.
Jesse J SwenDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands.
Dirk Jan A R MoesDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands. d.j.a.r.moes@lumc.nl.ORCID http://orcid.org/0000-0003-3219-253X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveTacrolimus therapeutic drug monitoring after kidney transplantation is primarily guided by the pre-dose concentration (C

methodsIn 534 kidney transplant recipients followed for up to 13 months post-transplantation, 635 tacrolimus pharmacokinetic profiles with corresponding C

resultsDespite comparable C

conclusionsTacrolimus C

Indexed as

Immunosuppressive AgentsKidney TransplantationTacrolimusAdultAgedArea Under CurveDose-Response Relationship, DrugDrug MonitoringFemaleHumansMaleMiddle AgedImmunosuppressive AgentsTacrolimus

Identifiers

PMID42487068
PMCPMC13545023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.